Investigational drug · Phase 2
ARCT-032
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cystic Fibrosis, CFTR Gene Mutation.
Phase 2Last checked: Nov 19, 2026Latest source record: May 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ARCT-032"
First trial start
2024
Dec 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ARCT-032", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cystic Fibrosis
- CFTR Gene Mutation
Approved drugs for the same conditions: Cystic fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "ARCT-032" as an intervention, largest first.
Arcturus Therapeutics, Inc.Industry
NCT05712538 · 39 participants · Start Feb 15, 2023 · Primary completion Jul 29, 2024
Drug: ARCT-032 · For: Cystic Fibrosis
Sites: Christchurch, New Zealand
Arcturus Therapeutics, Inc.Industry
NCT06747858 · 33 participants (planned) · Start Dec 12, 2024 · Primary completion Jun 2027
Drug: ARCT-032 · For: Cystic Fibrosis; CFTR Gene Mutation
Sites: Tucson, Arizona; Little Rock, Arkansas; Los Angeles, California · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review.
Ugwu OP, Ogenyi FC, Basajja M, et al. · Front Drug Deliv 2026
Also in development for Cystic Fibrosis
- VX-121D-IVA, CTP-656Phase 33 trials
Vertex Pharmaceuticals · Cystic Fibrosis
- CMTX-101Phase 21 trial
Clarametyx Biosciences, Inc. · Persistent Infection, Cystic Fibrosis
- ETD001Phase 21 trial
Enterprise Therapeutics Ltd · Cystic Fibrosis
- RCT2100Phase 21 trial
ReCode Therapeutics · Cystic Fibrosis
- SPL84Phase 21 trial
SpliSense Ltd. · Cystic Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.